These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8024657)

  • 41. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
    McKeage MJ; Raynaud F; Ward J; Berry C; O'Dell D; Kelland LR; Murrer B; Santabárabara P; Harrap KR; Judson IR
    J Clin Oncol; 1997 Jul; 15(7):2691-700. PubMed ID: 9215842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
    Ishibashi T; Yano Y; Oguma T
    Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologically guided phase I clinical trials based upon preclinical drug development.
    Collins JM; Grieshaber CK; Chabner BA
    J Natl Cancer Inst; 1990 Aug; 82(16):1321-6. PubMed ID: 2143234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and early clinical studies of selected new drugs.
    Kaye SB; Workman P; Graham MA; Cassidy J; Jodrell D
    Cancer Surv; 1993; 17():371-96. PubMed ID: 8137348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
    Budman DR; Meropol NJ; Reigner B; Creaven PJ; Lichtman SM; Berghorn E; Behr J; Gordon RJ; Osterwalder B; Griffin T
    J Clin Oncol; 1998 May; 16(5):1795-802. PubMed ID: 9586893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [To which criterion should the dosage of anticancer drug be adapted?].
    Desoize B
    Bull Cancer; 1993 May; 80(5):376-90. PubMed ID: 8173191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
    Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
    Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
    Furth AF; Mandrekar SJ; Tan AD; Rau A; Felten SJ; Ames MM; Adjei AA; Erlichman C; Reid JM
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):39-45. PubMed ID: 17909811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
    Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
    J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
    Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
    J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hidalgo M; Siu LL; Nemunaitis J; Rizzo J; Hammond LA; Takimoto C; Eckhardt SG; Tolcher A; Britten CD; Denis L; Ferrante K; Von Hoff DD; Silberman S; Rowinsky EK
    J Clin Oncol; 2001 Jul; 19(13):3267-79. PubMed ID: 11432895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics.
    Hoshino-Yoshino A; Kato M; Nakano K; Ishigai M; Kudo T; Ito K
    Drug Metab Pharmacokinet; 2011; 26(6):612-20. PubMed ID: 21897052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
    Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.